Insider Selling: Enfusion, Inc. (NYSE:ENFN) CEO Sells 11,452 Shares of Stock

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 11,452 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $11.39, for a total value of $130,438.28. Following the completion of the transaction, the chief executive officer now owns 631,847 shares of the company’s stock, valued at $7,196,737.33. This represents a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Oleg Movchan also recently made the following trade(s):

• On Monday, March 3rd, Oleg Movchan sold 2,790 shares of Enfusion stock. The shares were sold at an average price of $11.48, for a total value of $32,029.20.
• On Tuesday, January 7th, Oleg Movchan sold 2,771 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $28,070.23.

Enfusion Stock Performance

NYSE ENFN opened at $11.24 on Monday. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95. The stock’s 50 day moving average price is $10.98 and its two-hundred day moving average price is $9.90. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The company had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. On average, equities research analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current year.

Institutional Investors Weigh In On Enfusion

A number of institutional investors and hedge funds have recently made changes to their positions in ENFN. Harbor Capital Advisors Inc. raised its stake in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after purchasing an additional 1,315 shares in the last quarter. Versor Investments LP bought a new stake in shares of Enfusion during the 3rd quarter worth approximately $501,000. Impax Asset Management Group plc raised its stake in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Royce & Associates LP raised its stake in shares of Enfusion by 35.4% during the 3rd quarter. Royce & Associates LP now owns 99,715 shares of the company’s stock worth $946,000 after purchasing an additional 26,045 shares in the last quarter. Finally, Gladius Capital Management LP raised its stake in Enfusion by 160.5% in the 3rd quarter. Gladius Capital Management LP now owns 69,694 shares of the company’s stock valued at $661,000 after acquiring an additional 42,939 shares during the period. Institutional investors own 81.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ENFN shares. William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Piper Sandler boosted their target price on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus boosted their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.